GRFS Stock Analysis: Buy, Sell, or Hold?
GRFS - Grifois, S.A.
$8.23
-0.03 (-0.30%)
▼
5d:
+7.94%
30d:
-5.02%
90d:
-12.03%
BUY
HIGH Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: Apr 30, 2026
27d
Get Alerted When GRFS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: GRFS shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: GRFS shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$17.25
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$10.71
23.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 6.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GRFS is currently trading at $8.22, which is considered fair relative to its 30-day fair value range of $7.69 to $8.80. The stock's valuation (Forward PE: 6.3) is in line with its historical norms (6.8). Remarkably, the market is currently pricing in an annual earnings decline of 2.1% over the next few years. This pessimistic expectation contrasts with the company's recent 750.0% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, GRFS is in a downtrend. The price is approaching resistance at $8.28. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GRFS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $12.53 (+51.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GRFS is in a downtrend. The price is approaching resistance at $8.28. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GRFS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $12.53 (+51.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$7.69 -
$8.80
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
83.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 51.8% below Wall St target ($12.53)
Fair Price Analysis
30-Day Fair Range
$7.69 -
$8.80
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$7.39
Resistance Level
$8.28
Current Trend
Downtrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.33
Wall Street Target
$12.53
(+51.8%)
Revenue Growth (YoY)
4.0%
Earnings Growth (YoY)
750.0%
Profit Margin
5.0%
Valuation Discount vs History
-2.1% cheaper
PE vs Historical
6.3 vs 6.8
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.1%
(market-implied from PE analysis)
1-Year Target
$8.08
(-2%)
2-Year Target
$7.91
(-4%)
3-Year Target
$7.74
(-6%)
3-Yr Target (if PE normalizes)
(PE: 6→7)
$8.31
(+1%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 49.4%)
$97.15
(+1078%)
Base:
(SPY PE: 6.3, Growth: 49.4%)
$27.53
(+234%)
Bear:
(PE: 5.4, Growth: 49.4%)
$23.40
(+184%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (6x PE) as earnings recover.
Trailing PE: 13.81 | Current EPS (TTM): $0.63
Bull Case
$19.14
(+149%)
Analyst growth 100.0%, PE expands to 15.2
Base Case
$17.40
(+126%)
Market implied 100.0%, PE stable at 13.8
Bear Case
$5.92
(-23%)
Severe decline -20.0%, PE contracts to 11.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 6.3 to 6.8
Stabilization Target:
$8.86
(+7.4%)
PE Expansion Potential:
+7.4%
Share & Embed Analysis
Last updated: April 02, 2026 2:21 PM ET
Data refreshes hourly during market hours. Next update: 3:21 PM
Data refreshes hourly during market hours. Next update: 3:21 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GRFS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1209 | 57 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$157 | 60 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$249 | 59 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$206 | 55 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$351 | 54 HOLD |
